



CIN: L99999MH1951PLC008485

Regd. Office : 'dil' Complex, Ghodbunder Road, Majiwada, Thane (W) - 400 610, Maharashtra, India.

Tel.: +91-22-6798 0888 • Fax : +91-22-6798 0899 • Email : contact@dil.net • Website : www.dil.net

DIL Limited

| (₹. In Lakhs) | | | | | |
|---|---|---------------|---------------|---------------|---------------|
| STATEMENT OF STANDALONE / CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2017. | | | | | |
| Sr.No. | Particulars | Standalone | | Consolidated | |
| | | Quarter ended | | Quarter ended | |
| | | Unaudited | Unaudited | Unaudited | Unaudited |
| | | June 30, 2017 | June 30, 2016 | June 30, 2017 | June 30, 2016 |
| | | (Note 4) | | (Note 4) | |
| 1 | Revenue from operations | 184.40 | 177.13 | 4,395.68 | 4,278.94 |
| 2 | Other income | 7.45 | 34.27 | 15.20 | 30.26 |
| 3 | Total Income (1+2) | 191.85 | 211.40 | 4,410.88 | 4,309.20 |
| 4 | Expenses | | | | |
| a) | Cost of material consumed | - | - | 1,776.76 | 1,945.20 |
| b) | Purchase of stock in trade | - | - | (2.78) | 12.50 |
| c) | Change in inventories of finished goods, work in process and stock in trade | - | - | 314.61 | (337.48) |
| d) | Excise duty | - | - | 30.79 | 44.97 |
| e) | Employee benefits expense | 146.68 | 117.17 | 839.79 | 745.92 |
| f) | Finance costs | 161.17 | 169.75 | 266.45 | 254.69 |
| g) | Depreciation and amortisation expense | 92.95 | 80.41 | 276.17 | 241.58 |
| h) | Other expenses | 282.65 | 164.21 | 1,250.26 | 1,093.83 |
| | Total expenses (a to h) | 683.45 | 531.54 | 4,752.05 | 4,001.21 |
| 5 | Profit/(Loss) before exceptional items and tax (3 - 4) | (491.60) | (320.14) | (341.17) | 307.99 |
| 6 | Exceptional item | - | - | - | - |
| 7 | Profit/(Loss) before tax (6 - 7) | (491.60) | (320.14) | (341.17) | 307.99 |
| 8 | Tax expense | | | | |
| | Current tax | - | - | 33.69 | 113.44 |
| | Deferred tax (credit)/charge | - | 2.73 | (3.67) | (12.19) |
| 9 | Profit / (Loss) after tax for the period (7-8) | (491.60) | (322.87) | (371.19) | 206.74 |
| 10 | Other Comprehensive Income | | | | |
| (A) | (i) Items that will not be reclassified to Profit & Loss | - | 121.34 | - | 121.34 |
| | (ii) Income tax relating to items that will not be reclassified to Profit & Loss | - | - | - | - |
| (B) | Items that will be reclassified to Profit & Loss | - | - | - | - |
| 11 | Total Comprehensive Income (9+10) | (491.60) | (201.53) | (371.19) | 328.08 |
| 12 | Share of profit / (loss) of associates / Joint venture | - | - | (1.27) | (1.52) |
| 13 | Minority interest | - | - | (30.35) | (127.50) |
| 14 | Net Profit/ (Loss) after taxes, minority interest and share of profit/(loss) of associates / Joint venture (11+12+13) | (491.60) | (201.53) | (402.81) | 199.06 |
| 15 | Paid-up equity share capital (Face value Rs 10/- per share) | 229.32 | 229.32 | 229.32 | 229.32 |
| 16 | a) Basic and diluted earning per share of ₹10/- each before extraordinary items | (21.44) | (8.79) | (17.57) | 8.68 |
| | b) Basic and diluted earning per share of ₹10/- each after extraordinary items | (21.44) | (8.79) | (17.57) | 8.68 |


© For quarter only and not annualised except for year end results

SIGNED FOR IDENTIFICATION
BY
W
SRBC & CO LLP
MUMBAI

(W)

| Reporting of Segment-wise Revenue, Results and Capital employed | | Consolidated | |
|--|------------------|------------------|--|
| | | Quarter ended | |
| Particulars | Unaudited | Unaudited | |
| | June 30, 2017 | June 30, 2016 | |
| Segment revenue | | | |
| - Bulk drugs/chemicals | 4,232.49 | 4,103.88 | |
| - Property | 188.89 | 181.63 | |
| - Unallocated | 12.00 | 45.88 | |
| Total | 4,434.29 | 4,331.39 | |
| Less: Inter-segment revenue | 23.41 | 22.19 | |
| Net sales/income from operation | 4,410.88 | 4,309.20 | |
| Segment results (profit/(loss) after finance costs and before tax) | | | |
| - Bulk drugs/chemicals | 215.25 | 688.49 | |
| - Property | (246.25) | (97.01) | |
| - Unallocated | (314.74) | (278.52) | |
| Total | (345.74) | 312.96 | |
| Less: Inter-segment results | 4.57 | (4.97) | |
| Total Profit/(Loss) before tax | (341.17) | 307.99 | |
| Segment Assets | | | |
| - Bulk Drugs/chemicals | 17,528.00 | 16,298.86 | |
| - Property | 10,258.64 | 9,638.90 | |
| - Unallocated | 2,707.24 | 5,765.76 | |
| Total Segment Assets | 30,493.88 | 31,703.52 | |
| Segment liabilities (including borrowings) | | | |
| - Bulk Drugs/chemicals | 6,784.59 | 6,515.67 | |
| - Property | 5,435.26 | 5,890.34 | |
| - Unallocated | 4,464.68 | 3,821.61 | |
| Total Segment liabilities | 16,684.53 | 16,227.62 | |

Note: The Company on standalone basis has only one primary business segment viz. Renting of Properties



NOTES:

- 1 DIL Limited ('the Company') is in the business of renting properties. The Company also has strategic investments in subsidiaries, associates and joint ventures which are engaged in manufacturing of bulk drugs, providing services of sporting and health awareness/education activities, development of discoidal electrical motor technology and motion film production.

The above unaudited financial results are presented on a standalone basis as well as on a consolidated basis so as to include the operations of the Company's subsidiaries, associates and joint ventures.


The unaudited consolidated financial results include the result of one joint venture, one subsidiary and two associates on the basis of unaudited financial statements prepared by the Management.

- 2 The above results as reviewed by the Audit Committee have been approved at the meeting of the Board of directors held on 14th September, 2017 and have been subjected to Limited Review by the Statutory Auditors.
- 3 The Company adopted Indian Accounting Standard ("Ind AS") from April, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under. The date of transition to Ind AS is April 1, 2016. The impact of transition has been accounted for in opening reserves and the comparative period results have been restated accordingly. The opening balance sheet as at April 1, 2016 and the results for the subsequent periods would get finalised along with the annual financial statements for the year ended March 31, 2018.
- 4 The financial results and financial information for the quarter ended June 30, 2016 have not been audited or reviewed and have been presented based on the information compiled by the management after making the necessary adjustment to give a true and fair view in accordance with Ind AS.
- 5 The Company has not made any provision for impairment of its investments in two associates whose carrying value in standalone financial statements is ₹. 1,009.86 lakhs and in consolidated financial statement is ₹. 454.38 lakhs. In view of the fact that these investments have been made in the recent years and in spite of erosion of net worth, management is confident that profitability will be achieved by these entities and hence there is no impairment of these investments. Auditors have qualified their opinion in this regard.
- 6 During the previous quarter, the Company along with other new investors, invested ₹. 175 Lakhs in Zela Wellness India Private Limited (Zela) and acquired 83,634 equity shares of ₹. 10 each, consequently the company's equity holding in Zela Wellness India Private Limited (Zela) is revised to 29.50% as against earlier 49%.
- 7 Reconciliation of Net Profit as previously reported on account of transition from the previous GAAP to Ind AS for the quarter ended June 30, 2016.

| Particulars | (₹. in Lakhs) Standalone Unaudited | (₹. in Lakhs) Consolidated Unaudited |
|--|--|--|
| Net Profit After Tax for the period (as per previous GAAP) | (328.39) | 1.13 |
| Add/(Less): | | |
| Reversal of straight lining of rent and amortisation of prepaid rent | 13.34 | 13.17 |
| Unwinding of discounting on financial liabilities | (7.45) | (7.12) |
| Impact of effective interest rate on borrowings | (1.02) | (1.02) |
| Change in fair value of mutual fund investments | 3.22 | 3.22 |
| Actuarial gain/losses reclassified to OCI | 0.16 | 0.16 |
| Prior Period Item restated | - | 20.01 |
| Impact of expected credit loss model | - | 86.00 |
| Tax Impact of above items of Reconciliation | (2.73) | (37.83) |
| Profit After Tax as per Ind AS | (322.87) | 77.72 |
| Other Comprehensive Income (Net of Tax) | 121.34 | 121.34 |
| Total Comprehensive Income | (201.53) | 199.06 |

- 8 Previous period's figures have been regrouped wherever necessary.

Place: Thane
September 14, 2017



For DIL Limited


Krishna Datla
Managing Director